Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	251.36	56.81	70.17	31.16
Short-Term Investments	261.67	248.48	77.31	-
Cash & Short-Term Investments	513.03	305.28	147.48	31.16
Cash Growth	59.99%	107.00%	373.31%	-
Prepaid Expenses	7.53	0.3	1.5	0.11
Restricted Cash	0.11	0.11	0.09	-
Other Current Assets	-	4.12	1.81	-
Total Current Assets	520.66	309.8	150.87	31.27
Property, Plant & Equipment	13.6	4.97	4	0.34
Long-Term Deferred Charges	-	-	0.3	-
Other Long-Term Assets	1.07	0.16	0.25	-
Total Assets	535.32	314.93	155.42	31.6
Accounts Payable	3.24	1.95	2.5	1.45
Accrued Expenses	8.6	6.08	5.63	0.21
Current Portion of Leases	2.48	0.74	0.67	-
Total Current Liabilities	14.32	8.77	8.8	1.66
Long-Term Debt	-	-	4.2	10.44
Long-Term Leases	9.39	0.74	1.48	-
Total Liabilities	23.71	9.51	14.48	12.1
Common Stock	0.05	0.04	0	0.03
Additional Paid-In Capital	712.89	429.66	19.8	0.56
Retained Earnings	-201.47	-123.75	-45.44	-10.65
Comprehensive Income & Other	0.15	-0.52	0	-
Total Common Equity	511.62	305.43	-25.63	-10.06
Shareholders' Equity	511.62	305.43	140.94	19.51
Total Liabilities & Equity	535.32	314.93	155.42	31.6
Total Debt	11.87	1.48	6.35	10.44
Net Cash (Debt)	501.15	303.8	141.13	20.72
Net Cash Growth	57.10%	115.26%	581.01%	-
Net Cash Per Share	13.94	14.65	93.73	26.66
Filing Date Shares Outstanding	47.66	36.5	4.17	0.78
Total Common Shares Outstanding	47.65	36.58	4.17	0.78
Working Capital	506.34	301.04	142.07	29.61
Book Value Per Share	10.74	8.35	-6.15	-12.95
Tangible Book Value	511.62	305.43	-25.63	-10.06
Tangible Book Value Per Share	10.74	8.35	-6.15	-12.95
Machinery	4.49	3.78	1.76	0.3
Construction In Progress	0.06	0.43	0.03	0.06
Leasehold Improvements	0.28	0.28	0.26	-

Source: S&P Capital IQ. Standard template. Financial Sources.